ESSO-ESPSO, ISPSM & AGOI · peritoneal surface malignancies and to review important developments in fields of gynecological and colorectal cancers in last one year. The pre-conference

ESSO-ESPSO, ISPSM & AGOI

19 - 21 April 2019R D Choksi Auditorium,Tata Memorial Hospital, Parel, Mumbai

3rd INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER

5 CME Credit Points Awarded

Dr. Amita Maheshwari Organising Secretary

Dr. Sudeep Gupta Organising Chairman

Dr. Somashekhar SP Hon. Secretary, ISPSM

Dr. SVS Deo President, ISPSM

Dear Friends,rdIt is our pleasure to invite you to the 3 ESSO-ESPSO, ISPSM & AGOI International Course, Workshop &

Conference along with Year in Review in Gynecological and Colorectal malignancies, organized by the

Indian Society of Peritoneal Surface Malignancies (ISPSM) in collaboration with the Association of

Gynaecologic Oncologists of India (AGOI), from April, 19-21 at Tata Memorial Hospital, Mumbai

The scientific program has been carefully designed to present and discuss the most recent evidence in

peritoneal surface malignancies and to review important developments in fields of gynecological and

colorectal cancers in last one year. The pre-conference workshop will have a series of lectures covering

practical aspects of CRS & HIPEC followed by live surgical demonstration of CRS, HIPEC and PIPEC. The

first twenty delegates will also get an opportunity to get hands-on in wet lab.

The conference will feature keynote lectures, didactic sessions, panel discussions and satellite symposia.

Delegates will get a chance to meet and interact with renowned international and national faculty members.

The conference will also provide an opportunity to present original work during oral and poster presentation

sessions with exciting awards in both categories. The best oral and poster awardees will receive

international HIPEC travel fellowships to an European Centre under the guidance of an international faculty.

This conference is intended for gynecological, surgical and medical oncologists, oncology nurses and

technicians, perfusionists, pathologists and other healthcare professionals working in the field of

gynecological and gastrointestinal cancers.

We look forward to your active participation & support in making this meeting successful.

Regards

Dr. Shalini Rajaram President, AGOI

Dr. Avanish Saklani Co-organising Secretary

Dr. Manish Bhandare & Dr. Vikram Chaudhari Workshop Co-ordinators

rd3 INTERNATIONAL COURSE

WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER

19 - 21 April 2019, Mumbai

1

Live surgery - CRS & HIPEC

Live demonstration PIPAC

Hands on peritonectomy & HIPEC (Wet Lab - Limited Seats)

Symposia on targeted therapy in Ovarian & Colorectal Cancers

HIPEC machine - Technical aspects

Surgical videos

Preoperative optimization & nutrition

Comprehensive review of recent evidence on PSM and HIPEC

MDT case management with interactive voting on key topics

Year in review:

Ÿ Gynecologic Oncology

Ÿ Colorectal Cancer

Best Oral & Poster presentation awards (5 in each category)

International travel fellowships for Best Oral & Poster awardees

5 CME credit points

Highlights




2




INTERNATIONAL FACULTY

Dr. Vahan Kepenekian

Department of Surgical Oncology, CHU Lyon Sud, University of Lyon,

France

Dr. Vic Verwaal

Dr. Kusamura Shigeki Dr. Henk Schreuder

HIPEC Specialist,Department of GI SurgeryAarhus University Hospital,

Denmark

HIPEC Specialist,IRCCS Foundation National

Cancer Institute, Milan,Italy

Ass. Professor MD, PhD,Gynaecologies Oncologist at

University Medical Center,Utrecht, Netherlands

1




ISPSM Members

National Council Members

Dr. SVS Deo

Dr. Avanish Saklani

Dr. Mahesh B

Dr. Rama Joshi

Dr. Ashwin Rajagopal

Dr Subramanyeshwar Rao

AGOI Executive Committee

Dr. Aviram Nissan

Dr. Vic Verwaal

Dr. Pompiliu Piso

Dr. Marcello Deraco

Dr. Kusamura Shigeki

Dr. Olivier Glehen

Dr. Ignace de Hingh

Dr. Somashekhar S P

Dr. Harit Chaturvedi

Dr. Shivendra Singh

Dr. Amith Rauthan

Dr. Ganesh MS

Dr. Shabber Zaveri

Dr. Vikash Mahajan

Dr. Kapil Kumar

Dr. Amita Maheshwari

Dr. Ayappan

International Founding Members & Patrons

Dr. Kasturi Lal

Dr. Shalini Rajaram

Dr. Amita Maheshwari

Dr. Vijay Ahuja

Dr. Richa Chauhan

Dr. Satinder Kaur

Dr. Umesh Mahantshetty

Dr. S.B.L.Shrivastav

Dr. Uma Singh

Dr. Jita Parija

Dr. Sabhyata Gupta

Dr. Vinita Singh

Dr. Bhagyalaxmi Nayak

Dr. Rupinder Sekhon

Dr. Amrit Gupta

Dr. Geetha Nagasree

Dr. Nisha Singh

Dr. Ranu Patni

Dr. Janmejaya Mohapatra

Dr. Somashekhar SP

Dr. Yogesh Kulkarni

1

Live, Video Workshop & Wet Lab

Session 1 : The Basics

Session 2 : The Technique

Time Topic

07:45 - 08:15 Registration

08:15 - 08:45 Welcome and Introduction

Speakers: Somashekhar SP, Amita Maheshwari,

Sudeep Gupta, Vic Verwaal

08:45 - 09:50 Chairpersons: Chetan Kantharia, Dharmesh Balsarkar,

Manas Biswas

08:45 - 09:00 Pathophysiology of Peritoneal Surface Malignancies

Speaker: Kusamura Shigeki

09:00 - 09:15 Anatomy of Peritoneal Cavity

Speaker: Vic Verwaal

09:15 - 09:30 Pharmacology of HIPEC


09:30 - 09:40 PCI, CCR, PSS: Getting Them Right

Speaker: Vikash Mahajan

09:40 - 09:50 Q&A : Chairpersons & Speakers

09:50 - 11:10 Chairpersons: Manish Bhandare, Amish Dalal, Shylasree TS

09:50 - 10:05 Achieving Optimal Cytoreduction: Tips and Tricks

Speaker: Somashekhar SP

10:05 - 10:20 Techniques of CRS and HIPEC: Do’s & Dont’s


10:20 - 10:35 Setting up a CRS & HIPEC Program

Speaker: SVS Deo

Scientific Program - Day 1 Friday 19 April 2019, Mumbai


WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES

YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER

1


Time Topic

10:35 - 10:50 Pathophysiology and Approach to PMP and DMPM


10:50 - 11:00 Training and Fellowship Opportunities

Speaker: Snita Sinukumar

11:00 - 11:10 Q&A : Chairpersons & Speakers

11:10 - 11:25 Tea/Coffee Break

11:25 - 12:30 Chairpersons: Amish Chaudhary, R Rajagopalan, Umang Mithal

11:25 - 11:35 Total Parietal Peritonectomy in Peritoneal Mesothelioma


11:35 - 11:45 Management of Upper Abdomen Disease (Stripping of

diaphragm, Splenectomy, Distal pancreatectomy and partial

gastrectomy)


11:45 -11:55 Glisson Capsulectomy and Mesenteric Peritonectomy

Speaker: Vahan Kepenekian

11:55 - 12:05 Cytoreductive Surgery in Ovarian Cancer: Approach to Pelvic

Disease

Speaker: Schreuder Henk

12:05 - 12:15 EPIC

Speaker: Firoz Rajan

12:15 - 12:20 IP Port Placement in Ovarian Cancer

(Bard Sponsored Talk)

Speaker: Ashwin KR

12:20 -12:30 Q&A : Chairpersons & Speakers

12:30 - 13:15 Lunch

Session 3: Videos - How I do it

1






1

Time Topic

13:15 - 17:30 Moderators - CRC HIPEC: Surgeon:

Ganesh M S Kusamura Shigeki

P S Rao

T Subramanyeshwar Rao

K Chitrathara

Manish Bhandare (from OT)

Avanish Saklani (from OT)

JV Divatia (from OT)

Moderators - CRC PIPAC: Surgeon:

Sujai Hegde Ashwin KR

KVVN Raju

Ninad Katdare

Vikram Chaudhari (from OT)

Sohanlal Solanki (from OT)

Experts: Vic Verwaal, Vahan Kepenekian, Schreuder Henk

14:00 - 14:30 Science of Energy

Speaker: Nitin Thakur

Session 5 : Wet Lab (Sponsored by J&J ) at J&J Lab


Session 4 : Live Surgery - CRC/HIPEC/PIPAC


1

Chairpersons: Tapan Saikia, Sanjay Sharma, Avinash Deo

Panel Discussion on Gastric Cancer - Are We Winning Against

the Most Formidable Enemy

Moderator: TBA

Muzammil Shaikh, Vikas Otswal, Siddharth TurkarPanelist:

Ganesh Nagrajan, Ian Pinto, Nilesh Lokeshwar

Vasishth Maniar

Time Topic

19:00 - 19:35 Industry Symposium 1 - Eli Lilly

19:35 - 20:20 Industry Symposium 2 - Mylan

Chairpersons: Somashekhar SP, Sudeep Gupta

19:35 - 19:50 Anti-Angeogenic Strategies for Advanced Gynecological

Cancers

Speaker: Amit Rauthan

19:50 - 20:20 Panel Discussion on Selection of Optimal Biosimilar

Moderator: B K Smruti

Panelists: Reetu Jain, Jaydip Bhaumik, Jaya Ghosh

Bharat Bhosale, Tejinder Singh, Monisha Gupta,

Sandeep Batra

20:30 Onwards Cultural Program & Dinner at Ballroom, ITC Grand Central,

Parel, Mumbai

Local Folk Dance

Magic Show by Magician Dhaya

Industry Symposiums (Ballroom, ITC Grand Central, Parel)

Session 6 : Proffered Papers

Session 7 : Current Evidence for CRS & HIPEC in Colorectal, Gastric & Ovarian Cancers

Scientific Program - Day 2 Saturday 20 April 2019, Mumbai

Time Topic

08:00 - 09:00 Proffered Paper Presentation

Chairpersons: S K Giri, Rama Joshi, SVS Deo

Kusamura Shigeki, Vic Verwaal, Vahan Kepenekian Judges:

Schreuder Henk

09:00 - 09:20 PSOGI International Guidelines for Pseudomyxoma Peritonei

and Mesothelioma


09:20 - 10:40 Chairpersons: Anil Heroor, Shalini Rajaram, Vikram Chaudhari

09:20 - 09:30 PRODIGE 7 & ProphyloCHIP


09:30 - 09:40 COLOPEC & COMBATAC


09:40 - 09:50 GASTRIPEC & GASTRICHIP Trials

Speaker: Jagdish Kothari

09:50 - 10:00 OVHIPEC & TBD

Speaker: Schreuder Henk

10:00 - 10:40 Panel Discussion on Current Evidence for CRS & HIPEC in

Colorectal, Gastric & Ovarian Cancers

AS Ramakrishnan, Amita Maheshwari Moderators:

Vahan Kepenekian, Vic Verwaal, Deepak Chhabra, Panelists:

Kusamura Shigeki, Schreuder Henk,

Harit Chaturvedi, K Chitrathara, Yogesh Kulkarni

Shailesh Shrikhande, Avanish Saklani





1

Session 8 : Technical Intricacies of CRS & HIPEC


Time Topic

11:00 - 12:30 Chairpersons: Harshad Parasnis, Dilip Muduly

11:00 - 11:35 Panel Discussion on Imaging and Laparoscopic Evaluation

before CRS & HIPEC

Harit Chaturvedi Moderator:

Palak Popat, Kanika Gupta, Rupinder Sekhon, Panelists:

Shaikat Gupta, Geetha Nagasree,

Kusamura Shigeki, Ashwin De Souza

11:35 - 11:50 Challenges in Anaesthetic Management in HIPEC

Speaker: HS Murthy

11:50 -12:30 Panel Discussion on HIPEC: Procedural Nuances

(Kidney protection- Sodium Thiosulphate, Ideal temperature,

non-visible mets- ICG, prophylactic stoma)

Shivendra Singh Moderator:

Ganesh M S, Jagannath Dixit, Aditi Bhat, Panelists:

Caleb Harris, Vijay Ahuja, Jagdishwar Goud,

T Subramanyeshwar Rao, Vic Verwaal, MD Ray

12:30 - 13:00 Conference Inauguration

13:00 - 13:45 Lunch Break

13:45 - 14:25 Chairpersons: M D Ray, Pradeep Jain

13:45 - 14:05 Chemotherapy Regimens in HIPEC


14:05 - 14:25 PIPAC: Rationale, Indications, Preliminary Outcomes

(Capnomed Sponsored Talk)


Session 9 : PIPAC & Chemotherapy in HIPEC

1


Time Topic

14:25 - 15:35 Chairpersons: Shaikat Gupta, Caleb Harris

14:25 - 14:40 ERAS in Peritoneal Surface Malignancies

(Medtronic Sponsored Talk)


14:40 - 14:55 Supplemental PN in Surgical Patients

(Fresenius Kabi Sponsored Talk)

Speaker: Deepesh Aggarwal

14:55 - 15:10 How to Reduce Post-Operative Complications?

Speaker: T Subramanyeshwar Rao

15:10 - 15:25 Where are the Dangers in HIPEC?


15:25 - 15:35 Q&A: Chairpersons & Speakers


15:50 - 16:40 Chairpersons: Elizabeth Vallikad, J N Kulkarni, K Chitrathara

15:50 - 16:00 Manipal Comprehensive Cancer Center, Bengaluru

Speaker: Somashekhar SP

16:00 - 16:10 Rajiv Gandhi Cancer Center, New Delhi

Speaker: Rupinder Sekhon

16:10 - 16:20 All India Institute of Medical Sciences, New Delhi

Speaker: SVS Deo

16:20 - 16:30 Fortis Memorial Research Institute, Gurugram

Speaker: Rama Joshi

16:30 - 16:35 Indian RCT: Welcome Trial on IP and HIPEC

Speaker: Asima Mukhopadhyay

16:35 - 16:40 Q&A: Chairpersons & Speakers




Session 10 : Road to Enhanced Recovery

Session 11: Indian Experience with HIPEC

1


Time Topic

16:40 - 17:00 Core Diagnostics

Genomics & Next Generation Sequencing

Speaker: Aparna Dhar

17:00 - 17:50 Astrazeneca

Chairpersons: Hemant Malhotra, Sandeep Batra, Jaya Ghosh

17:00 - 17:20 PARP Inhibition in Ovarian Cancer

Speaker: T P Sahoo

17:20 - 17:50 Panel Discussion on PARP Inhibition in Ovarian Cancer

Shona NagModerator:

: Amit Agarwal, Govind Babu, Rama Joshi,Panelists

Sachin Hingmire, Sudeep Gupta, Sabhayta Gupta,

Satinder Kaur, Somashekhar SP

17:50 - 18:10 Positive Biosciences - Myriad

BRCA Testing – Indian Scenario Myriad

Speaker: Karla Bowles

18:10 - 18:40 ISPSM GBM

19:30 Onwards Cultural Program & Dinner at Terrace Garden, ITC Grand

Central, Parel, Mumbai

Kavya Ajit & Band

Session 12: Industry Symposiums

1

Scientific Program - Day 3 Sunday 21 April 2019, Mumbai

The Year That Was (TYTW) - Gynecological Cancers (Hall A)

Session 13: Quiz for PG students

Time Topic

08:00 - 08:45 JudgesCoordinators

Elizabeth VallikadK ChitratharaAmrit Gupta

Jaya GhoshSeema Gulia

Session 14: Preventive and Primary Care

08:45 - 08:55

Chairpersons : Janmejaya Mohapatra, Elizabeth Vallikad

Reviewer: Neha Kumar

08:45 - 09:45




Abstract 1Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women.Laniewski P, et al., Sci Rep 2018; 8: 7593

Abstract 2Relationship between the Cervical Microbiome, HIV Status and Precancerous Lesions. Klein C, et al.,MBio. 2019 Feb 19;10(1)

Abstract 3Hand-to-genital and genital-to-genital transmission of human papillomaviruses between male and female sexual partners (HITCH): a prospective cohort study. Talía Malagón et al., Lancet Infect Dis 2019

Abstract 4Five-Year risk of cervical precancer following p16/Ki-67 dual-stain triage of HPV-positive women. Megan A. Clarke, et al., JAMA Oncol. 2019;5(2):181-186

Abstract 5Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Nicole J Polman, et al.,Lancet Oncol. 2019 Feb;20(2):229-238

1

Master

Sudeep Gupta


08:55 - 09:05

09:05 - 09:15

Reviewer: Veena Ranjan

Reviewer: Vinotha Thomas

Time Topic

Abstract 6Trends in human papillomavirus vaccine types 16 and 18 in Cervical precancers, 2008–2014Nancy M. McClun, et al.,Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):602-609

Abstract 7Screening for cervical cancer: US preventive services task force recommendation statement. Curry SJ, et al.,JAMA. 2018 Aug 21;320(7):674-686

Abstract 8Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the us preventive services task force. Melnikow J, et al., JAMA. 2018 Aug 21;320(7):687-705

Abstract 9Association between polycystic ovary syndrome and cancer risk. Yin W1, et al.,JAMA Oncol. 2019 Jan 1;5(1):106-107

Abstract 10Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. Lisa Iversen, et al.,BMJ. 2018 Sep 26;362:k3609

Abstract 11Risk of malignant ovarian cancer based on ultrasonography findings in a large unselected population. Smith-Bindman R, et al.,JAMA Intern Med. 2019 Jan 1;179(1):71-77

Abstract 12Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. Froyman W, et al.,Lancet Oncol. 2019 Mar;20(3):448-458

Abstract 13US preventive services task force recommendation statement. Screening for ovarian cancerJAMA. 2018; 319(6):588-594


1


09:15 - 09:45 Panel Discussion

Moderator: Shalini Rajaram

Panelists: Kavita Singh, Latha Balasubramani, Usha Saraiya,Sarita Bhalerao, Sangeeta Pankaj, Smita Joshi, Santosh Menon, Mukund Joshi

Session 15: Ovarian Cancer

09:45 - 10:00

Chairpersons: S H Advani, S K Giri, R A Kerkar

Time Topic

09:45 - 11:15




Reviewer: Rohit Ranade

Abstract 1Correlation between surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.Ramez N. Eskander, et al.,Gynecol Oncol. 2018 Jun;149(3):525-530

Abstract 2A phase III randomized controlled trial of secondary surgical cyto reduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. Robert L Coleman, et al.,ASCO 2018,JCO.2018.36.15_suppl.5501

Abstract 3A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms.philipp Harter, et al.,N Engl J Med. 2019 Feb 28;380(9):822-832

Abstract 4Hyperthermic intraperitoneal chemotherapy in ovarian cancer. Willemien J. van Drier January 18, 2018. N Engl J Med 2018; 378:230-240


1


10:00 - 10:10

10:10 - 10:20

Time Topic

Abstract 5Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. Foster JM,et al.,JAMA Netw Open. 2019 Jan 4;2(1):e186847

Reviewer : Amit Agarwal

Abstract 6Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)Anna Fagotti, et al.,JCO 36, no. 15_suppl (May 20 2018) 5516-5516

Abstract 7Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602Takachi Onda,et al.,JCO 36, no. 15_suppl (May 20 2018) 5500-5500

Abstract 8Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.Ignace Vergote, et al.,Lancet Oncol. 2018 Dec;19(12):1680-1687

Reviewer: Sachin Hingmire

Abstract 9AGO OVAR 2.21. A prospective randomized Phase III trial of Carboplatin / Gemcitabine / Bevacizumab vs. Carboplatin / Pegylated Liposomal Doxorubicin / Bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. An ENGOT / GCIG Trial.ESMO 2018,Abstract 933OJ. Pfisterer, et al.,Annals of Oncology (2018) 29 (suppl_8): viii332-viii358

Abstract 10Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: A randomized clinical trial. Falchook G, et al.,JAMA Oncol. 2019 Jan 1;5(1):e183773


1


10:20 - 10:30

Time Topic




Abstract 11Paclitaxel with and without pazopanib for persistent or recurrent ovariancancer: A randomized clinical trial.Debra L., et al.,JAMA Oncol. 2018; 4(2):196-202

Abstract 12Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Vergote I, et al.,Gynecol Oncol. 2018 Sep;150(3):471-477

Reviewer: Sandeep Batra

Abstract 13Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.Moore K, et al., N Engl J Med. 2018 Dec 27;379(26):2495-2505

Abstract 14Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial Michael Friedlander, et al.,Lancet Oncol. 2018 Aug;19(8):1126-1134

Abstract 15Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2018. Amit M Oza, et al.,Lancet Oncol. 2018 Aug;19(8):1117-1125

Abstract 16TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort. Panagiotis A,et al., ASCO 2018,Abstract 106.JCO 36, no. 15_suppl (May 20 2018) 106-106


1


10:30 - 10:40

10:40 - 11:15

Time Topic


Session 16: Uterine Cancer

Reviewer: Sudeep Gupta

Abstract 17BRCA Challenge: BRCA exchange as a global resource for variants in BRCA1 and BRCA2.Cline MS, et al.,PLoS Genet. 2018 Dec 26;14(12):e1007752.

Abstract 18Accurate classification of BRCA1 variants with saturation genome editing.Gregory M. Findlay, et al.,Nature. 2018 Oct;562(7726):217-222

Abstract 19Molecular profiling of ovarian germ cell tumors.M. Stasenko, et al.,SGO 2018,Abstract 42

Panel Discussion Moderators: Senthil Rajappa, Yogesh KulkarniPanelists: Schreuder Henk, T P Sahoo, G S Bhattacharyya, Hemant Malhotra, Govind Babu, Seema Gulia, Kusamura Shigeki, Harshad Parasnis, Prashant Nyati

11:30 - 11:45

Chairpersons: S K Shrivastava, Prachi Thakar, Geetha Balsarkar11:30 - 12:35

Reviewer: Ranu Patni

Abstract 1Association of endometrial cancer risk with postmenopausal bleeding in women: A systematic review and meta-analysis.Clarke MA,et al., JAMA Intern Med. 2018 Sep 1;178(9):1210-1222

Abstract 2Evaluation of liquid from the papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.Wang Y,et al.,Sci Transl Med. 2018 Mar 21;10(433)


1


11:45 - 11:55

11:55 - 12:05

Time Topic




Abstract 3Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial.Frumovitz M, et al.,Lancet Oncol. 2018 Oct;19(10):1394-1403

Abstract 4Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?F.J. Backes, et al. Gynecologic Oncology 149:7-8.June 2018 (SGO 2018)

Abstract 5GOG 244, the lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients.J.W. Carlsona, et al.,Abstract 11,SGO 2018

Reviewer: Kaustav Talapatra

Abstract 6Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. PORTEC study group.de Boer SM,et al., Lancet Oncol. 2018 Mar;19(3):295-309

Abstract 7Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203.Jklopp AH,et al.,J Clin Oncol. 2018 Aug 20;36(24):2538-2544

Reviewer: Chetan Deshmukh

Abstract 8Single-course methotrexate and single-course combined methotrexate–dactinomycin: A phase III randomized controlled clinical trial in treatment of low-risk gestational trophoblastic neoplasm.L. Chena, et al., Gynecologic Oncology 149:20.June 2018.(SGO 2018)


1

12:35 - 12:45

Chairpersons: J N Kulkarni, Jita Parija, Latha Balasubramani12:35 - 13:50


12:05 - 12:35

Time Topic

Session 17: Cervical Cancer

Abstract 9The impact of uterine re-curettage on the number of chemotherapy courses in treatment of post molar gestational trophoblastic neoplasia: A randomized controlled studyR. Hemidaa, et al.,Abstract 41,SGO 2018

Abstract 10TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: preliminary outcomes in cohort A. LYou BM.et al.,BA35, ESMO 2018

Panel Discussion Moderators: Nitesh Rohatgi,Satinder KaurPanelists: Sampada Desai, Richa Chauhan, Anupama Rajanbabu, Umesh Mahantshetty, Amit Agarwal, Manish Siddha, Rupinder Sekhon, K Chitrathara

Reviewer: Umesh Mahantshetty

Abstract 1Revised FIGO staging for carcinoma of the cervix uteri.Bhatla Net al.,Int J Gynaecol Obstet. 2019 Apr;145(1):129-135.

Abstract 2High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study.Lei J,,et al.,PLoS Med. 2018 Oct 1;15(10)

Abstract 3Circulating human papillomavirus DNA as a biomarker of response in patients with locally advanced cervical cancer treated with definitive chemoradiation.Kathy Han,et al.,JCO Precision Oncology - published online September 13, 2018


1


Time Topic

12:45 - 12:55

12:55 - 13:10




Reviewer: Manas Biswas

Abstract 4LACC trial minimally invasive versus abdominal radical hysterectomy for cervical cancer. november 15, 2018 N Engl J Med 2018. (To also integrate the LACC Abstract IGCS c/o AM & LACC Abstract IGCS c/o AM in the same presentation)Pedro T. Ramirez, et al.,N Engl J Med 2018; 379:1895-1904

Abstract 5Survival after minimally invasive radical hysterectomy for early-stage cervical cancer.Melamed A,et al.,N Engl J Med 2018;379:1905-1914

Abstract 6Outcomes and costs of open, laparoscopic and laparoscopic radical hysterectomy for stage 1B1 cervical cancer.Margul DJ, et al.,Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5502-5502.

Abstract 7Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.Jkim SI, et al.,Gynecol Oncol. 2019 Jan 12.

Reviewer: Supriya Chopra

Abstract 8Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: A randomized controlled trial.Gupta S, et al. J Clin Oncol. 2018 Jun 1;36(16):1548-1555

Abstract 9Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: A randomized clinical trialShrivastava S et al.,JAMA Oncol. 2018 Apr 1;4(4):506-513


1


Time Topic

13:10 - 13:50

Session 18: Rapid Review

13:50 - 14:00

Chairpersons: Geetha Nagasree, G S Bhattacharyya, Hemant Tongaonkar

13:50 - 14:10

Abstract 10Randomized trial of adjuvant chemotherapy versus concurrent chemoradiotherapy in early-stage cervical cancer after radical surgery: A Chinese Gynecologic Oncology Group study (CSEM-002).D. Wenga, et al. SGO 2018

Abstract 11Association of definitive pelvic radiation therapy with survival among patients with newly diagnosed metastatic cervical cancer.Yuefeng Wang, et al., JAMA Oncol. 2018;4(9):1288-1291.

Abstract 12Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study Hyun Cheol Chung,et al.,Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5522-5522

Panel Discussion Moderator: Amita Maheshwari Panelists: Hemant Tongaonkar, Sudeep Gupta, Supriya Chopra, Chetna Bakshi, Roshni Pande, Yogesh Kulkarni, S K Giri, R A Kerkar, Kedar Deodhar

Reviewer: Sabhyata Gupta

Abstract 1Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. Lu HM, Li S, Black MH, Lee S, Hoiness R, Wu S, Mu W, Huether R, Chen J, Sridhar S, Tian Y, McFarland R, Dolinsky J, Tippin Davis B, Mexal S, Dunlop C, Elliott A. JAMA Oncol. 2018 Aug 16.

Abstract 2Oral contraceptive use and risks of cancer in the NIH-AARP diet and health study. Michels KA, Brinton LA, Pfeiffer RM, Trabert B. Am J Epidemiol. 2018 Aug 1;187(8):1630-1641


1

Abstract Numbering


Time Topic

14:00 - 14:10




Abstract 3Hormone replacement therapy after Oophorectomy and breast Cancer risk among BRCA1 mutation carriers.Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group. JAMA Oncol. 2018 Aug 1;4(8):1059-1065

Abstract 4Different menopausal hormone regimens and risk of breast cancer. Brusselaers N, Tamimi RM, Konings P, Rosner B, Adami HO, Lagergren J.Ann Oncol. 2018 Aug 1;29(8):1771-1776.


1

14:30 Onwards

Reviewer: Seema Gulia

Abstract 5Oncological management and obstetric and neonatal outcome5 for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Jorine de Haan, Magali Verheecke, Kristel Van Calsteren, Ben Van Calster, Roman G Shmakov, Mina Mhallem Gziri, and others. The Lancet Oncology, Vol. 19, No. 3, p337–346

Abstract 6Fertility preservation in patients with cancer: ASCO clinical practice guideline update. Kutluk Oktay, Brittany E. Harvey, Ann H. Partridge, Gwendolyn P. Quinn, Joyce Reinecke, Hugh S. Taylor, W. Hamish Wallace, Erica T. Wang, Alison W. Loren. JCO JUL 2018

Abstract 7Outpatient talc administration by Indwelling pleural catheter for malignant effusion. Rahul Bhatnagar, Ph.D April 5, 2018 N Engl J Med 2018; 378:1313-1322

Abstract 8Association between ultraprocessed food consumption and risk of mortality among middle-aged adults in france. Schnabel L, Kesse-Guyot E, Allès B, Touvier M, Srour B, Hercberg S, Buscail C, Julia C. JAMA Intern Med. 2019 Feb 11.

Awards Distribution & Valedictory Lunch

14:10 - 14:30


Time Topic

08.00- 08:40 Free Papers

Judges: A S Ramakrishnan, Pravin Kammar, Anil Heroor

Shivendra Singh

08:40 - 09:10 Debate on CME (complete mesocolic excision) for Colon Cancer

K PrakashFor CME:

Jean MenezesAgainst CME:

Caleb Harris, Kamlesh Verma, Anil Heroor,Panelists:

Jagannath Dixit, Manoj Mulchandani

09:10 - 09:40 Debate on Neoadjuvant Chemotherapy and Locally Advanced

Colon Cancer

TP SahooFor Therapy :Neoadjuvant

Rohin MittalFor Upfront Surgery:

Aruna Prabhu, Deepak Chhabra,Panelists:

Joseph Sequeira

09:40 - 10:10 Debate on Long Course Radiation Vs Short Course Radiation

With 4 Cycles Chemotherapy

Shirley LewisFor SCRT:

Shivendra Singh For LCRT:

Jagdishwar Goud, Karthik Vallam, Pavan Sugoor, Panelists:

Sharmila Agarwal, Karthick Rajamanickam

10:10 - 10:30 Molecular Profiling & Genomics in Colorectal Cancer

(SRL Sponsored Talk)

Speaker: BR Das


Session 13 - Controversies in Colorectal Cancer Hall B

1

Time Topic

10:45 - 11:05 What is the Way Forward Following the Recent Negative

RCT’s on CRS + HIPEC in colorectal cancer

10 mins Vic VerwaalDenmark Group View:

10 mins Vahan KepenekianFrench Group View:

Factors Affecting Morbidity in HIPEC, Analysis of 300 Cases

in Indian Patients

Speaker: Somashekar SP

Panelists: Ninad Katdare, Amit Gandhi, Amish Dalal,

Anup Tamhankar Suraj Pawar,

11:20 - 11:30 Complete Peritonectomy Versus Selective Peritonectomy in

Peritoneal Carcinomatosis Secondary to Colo-rectal Cancer-

Prospective Comparative Analysis of Outcomes

Speaker: Ashwin KR

Panelists: Ninad Katdare, Amit Gandhi, Amish Dalal,

Anup Tamhankar Suraj Pawar,

11:30 -12:00 Debate on Consolidation Chemotherapy in LARC Who Remain

CRM Positive After CTRT

TP SahooFor Consolidation Chemo:

A S RamakrishnanAgainst Consolidation Chemo :

Debashish Chaudhary, Ashish Pokharkar, Panelists:

Snita Sinukumar, Bhavesh Poladia

12:00 - 12:30 Debate on Multiple Resectable Liver Metastasis and Colon

Cancer: Neoadjuvant Chemo Vs. Upfront Surgery and Adjuvant

Viraj LavingiaFor Neoadjuvant Chemo:

Rajiv BhattFor Upfront Surgery:

Mahesh Goel, Rakesh Rai, Ganesh Nagarajan, Panelists:

Kamlesh Verma, Prasad Waghle





Hall B

1


Hall B

Time Topic

Chairpersons: C Ramchandra, Jagdishwar Goud, Somashekhar SP

12:30 - 12:45 Ovarian Preservation in CRC

Speaker: Shylasree TS

12:45 - 13:00 Current Role of Robotic in Colorectal Surgery

Speaker: Avanish Saklani

13:00 - 13:30 Debate on Robotic Rectum or Laparoscopic Rectal Resection

Venky MunikrishnanFor Robotic:

Pradeep Jain For Laproscopic:

Sivasanker MS, K Prakash, Kalyan MathaPanelists:

Somashekhar SP, Shaikat Gupta

13:30 - 14:00 Debate on T3 NO/ N1 Rectum CRM Free : Upfront Surgery vs

Neoadjuvant Therapy

Sanket Mehta For Upfront Surgery:

Manish SiddhaFor Neoadjuvant Therapy:

Nitin Singhal, Sudhir Jatal, Jagdish Kothari, Panelists:

Deepanjali Adulkar, Shirley Lewis

14:00 - 14:30 Debate on Wait and Watch for Rectal Cancer

Reena Engineer For :

Jagdish KothariAgainst:

Karthik Vallam, Deepti Mishra, Ritesh Pruthy, Panelists:

Sanjay Dudhat, Manish Siddha

14:30 onwards Veledictory & Vote of Thanks

1

REGISTRATION DETAILS

Category

ESSO/AGOI/ISPSM Members

Non-Members

Students & Trainees

21 March 2019

Category

Non-Members

Students & Trainees

Category

Non-Members

Students & Trainees

22 March - 15 April 2019

2000

3000

1500

2500

3500

2000

21 March 2019

3000

4000

1500

3500

4500

2000

Spot

5000

6000

3500

Spot

21 March 2019

4500

6500

2500

5500

7500

3500

Spot

Only Workshop (19 April 2019)

Only Conference (20 - 21 April 2019)

Workshop + Conference (19 - 21 April 2019)








1

Conference Secretariat: Anshul BishnoiRIVER ROUTE CREATIVE GROUP LLPUnit No. 9, Cama Industrial Premises Co-op Society Ltd. Sunmill Compound, Lower Parel (W), Mumbai - 400 013Tel: +91 22 24931357/58 Email: [email protected]

For online registration visit our website: www.ispsm19.com

Make NEFT on below details

Beneficiary name : ISPSM

Beneficiary Bank account No : 04852010065966

Beneficiary Bank Name : Syndicate Bank

Beneficiary Bank Branch : Manipal Hospital, Bangalore - 560017

IFSC code of Payee Bank : SYNB0000485

PAN No. : AABAI1853R

For offline registration send a DD/Cheque in favor of “ISPSM” along with duly filled registration

form to below address of conference secretariat.

Note:

Cancellation with 75% refund will be entertained until 31 March 2019.

After NEFT kindly send filled registration form to [email protected]




Documents

ESSO-ESPSO, ISPSM & AGOI · peritoneal surface malignancies and to review important developments in fields of gynecological and colorectal cancers in last one year. The pre-conference